Evidence map›Paper›PMID 38693476›Full record

ArticleBMC genomics2024

DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus.

Chantal B F Vogels, Verity Hill, Mallery I Breban, Chrispin Chaguza, Lauren M Paul, Afeez Sodeinde, Emma Taylor-Salmon, Isabel M Ott, Mary E Petrone, Dennis Dijk and 21 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Evidence of dengue virus transmission and a diversebioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 3 countries.

Chantal B F Vogels *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA. chantal.vogels@yale.edu.
Verity Hill *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Mallery I BrebanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Chrispin ChaguzaDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Lauren M PaulDepartment of Biological Sciences, College of Arts and Sciences, Florida Gulf Coast University, Fort Myers, Florida, USA.
Afeez SodeindeDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Emma Taylor-SalmonDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Isabel M OttDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Mary E PetroneDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Dennis DijkDepartment of Medical Microbiology & Infection Prevention, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
Marcel JongesDepartment of Medical Microbiology & Infection Prevention, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
Matthijs R A WelkersDepartment of Medical Microbiology & Infection Prevention, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
Timothy LocksmithBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Yibo DongBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Jacksonville, FL, USA.
Namratha TarigopulaBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Jacksonville, FL, USA.
Omer TekinBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Jacksonville, FL, USA.
Sarah SchmedesBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Jacksonville, FL, USA.
Sylvia BunchBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Natalia CanoBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Rayah JaberBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Charles PanzeraBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Ian StrykerBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Julieta VergaraBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Rebecca ZimlerBureau of Epidemiology, Division of Disease Control and Health Protection, Florida Department of Health, Tallahassee, FL, USA.
Edgar KoppBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Lea HeberleinBureau of Public Health Laboratories, Division of Disease Control and Health Protection, Florida Department of Health, Tampa, FL, USA.
Kaylee S HerzogDepartment of Epidemiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Joseph R FauverDepartment of Epidemiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Andrea M MorrisonBureau of Epidemiology, Division of Disease Control and Health Protection, Florida Department of Health, Tallahassee, FL, USA.
Scott F MichaelDepartment of Biological Sciences, College of Arts and Sciences, Florida Gulf Coast University, Fort Myers, Florida, USA.
Nathan D GrubaughDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA. nathan.grubaugh@yale.edu.
Florida Department of Health · USYale University · USAmsterdam University Medical Centers · NLFlorida Gulf Coast University · USUniversity of Nebraska Medical Center · USGGD Amsterdam · NL

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Predoctoral Training Program in VirologyT32AI055403 · NIAID · YALE UNIVERSITY · PI KUMAR, PRITI, MOTHES, WALTHER H · 2003 to 2024
$3.6M
Enhancing dengue virus genomic surveillance to uncover circulating genetic diversityDP2AI176740 · NIAID · YALE UNIVERSITY · PI GRUBAUGH, NATHAN DALE · 2022 to 2025
$2.5M
Novel organic-ion-based technology for long-term virus preservation at ambient temperatureR21GM142011 · NIGMS · FLORIDA GULF COAST UNIVERSITY · PI MICHAEL, SCOTT F, MIRJAFARI, ARSALAN · 2022 to 2023
$341k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS DP2 AI176740NIAID NIH HHS T32 AI055403NIGMS NIH HHS R21 GM142011NIGMS NIH HHS R21GM142011NIH HHS T32AI055403
6 · The paper itself

Abstract

backgroundThe increasing burden of dengue virus on public health due to more explosive and frequent outbreaks highlights the need for improved surveillance and control. Genomic surveillance of dengue virus not only provides important insights into the emergence and spread of genetically diverse serotypes and genotypes, but it is also critical to monitor the effectiveness of newly implemented control strategies. Here, we present DengueSeq, an amplicon sequencing protocol, which enables whole-genome sequencing of all four dengue virus serotypes.

resultsWe developed primer schemes for the four dengue virus serotypes, which can be combined into a pan-serotype approach. We validated both approaches using genetically diverse virus stocks and clinical specimens that contained a range of virus copies. High genome coverage (>95%) was achieved for all genotypes, except DENV2 (genotype VI) and DENV 4 (genotype IV) sylvatics, with similar performance of the serotype-specific and pan-serotype approaches. The limit of detection to reach 70% coverage was 10-100 RNA copies/μL for all four serotypes, which is similar to other commonly used primer schemes. DengueSeq facilitates the sequencing of samples without known serotypes, allows the detection of multiple serotypes in the same sample, and can be used with a variety of library prep kits and sequencing instruments.

conclusionsDengueSeq was systematically evaluated with virus stocks and clinical specimens spanning the genetic diversity within each of the four dengue virus serotypes. The primer schemes can be plugged into existing amplicon sequencing workflows to facilitate the global need for expanded dengue virus genomic surveillance.

Indexed as

Dengue VirusGenome, ViralSerogroupWhole Genome SequencingDengueGenotypeHigh-Throughput Nucleotide SequencingHumansRNA, ViralRNA, ViralAmplicon sequencingDengue virusGenomic surveillanceNext-generation sequencingWhole-genome sequencing

Identifiers

PMID38693476
PMCPMC11062901
OpenAlexW4396546394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.